Answers are grounded in this paper and cite their sources.
Background Drug-eluting sinus implants provide sustained local corticosteroid delivery after functional endoscopic sinus surgery (FESS), but comparative evidence relative to systemic corticosteroid therapy remains limited. This study aimed to compare postoperative outcomes between these strategies in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Methods This retrospective cohort included 129 patients treated between January 2022 and December 2024. Patients were classified into the drug-eluting sinus implant group, which underwent FESS with drug-eluting sinus implants (n = 68), and the oral methylprednisolone group, which underwent FESS followed by a 15-day oral methylprednisolone taper (n = 61). Both groups received the same routine postoperative care. The primary outcome was longitudinal change in the Sino-Nasal Outcome Test-22 (SNOT-22) score through Month 12. Secondary outcomes included visual analog scale (VAS) symptom scores, endoscopic healing outcomes, postoperative complications, and steroid-related adverse events. Biomarker changes were exploratory outcomes. Results SNOT-22 scores improved in both groups. At Month 12, the model-based between-group difference in change was −11.86 points (95% confidence interval [CI], −14.82 to −8.90; Holm-adjusted P < 0.001), with a similar multivariable-adjusted estimate (−11.32 points; 95% CI, −14.61 to −8.04; P < 0.001). Improvements in all five VAS symptom domains were greater in the drug-eluting sinus implant group after multiplicity correction. Compared with the oral methylprednisolone group, the drug-eluting sinus implant group had lower adjusted odds of synechiae or adhesion at Month 3 (adjusted odds ratio [OR], 0.09; 95% CI, 0.02–0.43) and ostial stenosis or obstruction at Month 6 (adjusted OR, 0.20; 95% CI, 0.06–0.65). Steroid-related adverse events occurred in 2.9% of patients in the drug-eluting sinus implant group and 16.4% of those in the oral methylprednisolone group (P = 0.013). Most inflammatory and type 2 biomarkers showed greater reductions at Month 3 in the drug-eluting sinus implant group after false discovery rate correction. Conclusion Compared with oral methylprednisolone, drug-eluting sinus implants was associated with greater symptom improvement, more favorable postoperative healing outcomes, fewer steroid-related adverse events, and greater reductions in several inflammatory biomarkers. Prospective controlled studies are needed to confirm these associations.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: